April 2024
1. ZHAN Y, Guo J, Yang W, Goncalves C, et al
   MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.
   J Clin Invest. 2024;134:e181338.
   

   >> Share

   
   February 2024
2. WU M, Hanly A, Gibson F, Fisher R, et al
   The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.
   J Clin Invest. 2024 Feb 1:e171063. doi: 10.1172/JCI171063.
   

   >> Share

   
   December 2023
3. KNIGHT DA, Ngiow SF, Li M, Parmenter T, et al
   Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
   J Clin Invest. 2023;133:e177489.
   

   >> Share

   
   November 2023
4. AJITH A, Mamouni K, Horuzsko DD, Musa A, et al
   Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance.
   J Clin Invest. 2023;133:e167951.
   

   >> Share

   
   August 2023
5. HUANG F, Cai F, Dahabieh MS, Gunawardena K, et al
   Peroxisome disruption alters lipid metabolism and potentiates anti-tumor response with MAPK-targeted therapy in melanoma.
   J Clin Invest. 2023 Aug 24:e166644. doi: 10.1172/JCI166644.
   

   >> Share

   
   July 2023
6. OZBAY KURT FG, Lasser S, Arkhypov I, Utikal J, et al
   Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target.
   J Clin Invest. 2023;133:e170762.
   

   >> Share

   
   January 2023
7. HUUHTANEN J, Kasanen HH, Peltola K, Lonnberg T, et al
   Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients.
   J Clin Invest. 2023 Jan 31:e164809. doi: 10.1172/JCI164809.
   

   >> Share

   
   July 2022
8. HICKMAN A, Koetsier J, Kurtanich T, Nielsen MC, et al
   LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade.
   J Clin Invest. 2022;132.
   

   >> Share

   
   June 2022
9. HUANG H, Nie C, Liu XF, Song B, et al
   Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.
   J Clin Invest. 2022 Jun 21. pii: 157726. doi: 10.1172/JCI157726.
   

   >> Share

   
   May 2022
10. PAL S, Perrien DS, Yumoto T, Faccio R, et al
    The microbiome restrains melanoma bone growth by promoting intestinal NK and Th1 cells homing to bone.
    J Clin Invest. 2022 May 3. pii: 157340. doi: 10.1172/JCI157340.
    

    >> Share

    
    
11. PAGLIANO O, Morrison RM, Chauvin JM, Banerjee H, et al
    Tim-3 mediates T cell trogocytosis to limit antitumor immunity.
    J Clin Invest. 2022;132.
    

    >> Share

    
    April 2022
12. CHEN D, Le SB, Hutchinson TE, Calinescu AA, et al
    Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma.
    J Clin Invest. 2022;132.
    

    >> Share

    
    January 2022
13. XU J, Su SM, Zhang X, Chan UI, et al
    ATP11B inhibits breast cancer metastasis in a mouse model by suppressing externalization of non-apoptotic phosphatidylserine.
    J Clin Invest. 2022 Jan 13. pii: 149473. doi: 10.1172/JCI149473.
    

    >> Share

    
    November 2021
14. KRISTENSEN NP, Heeke C, Tvingsholm SA, Borch A, et al
    Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive transfer with tumor-infiltrating lymphocytes in melanoma.
    J Clin Invest. 2021 Nov 23. pii: 150535. doi: 10.1172/JCI150535.
    

    >> Share

    
    
15. MA B, Akosman B, Kamle S, Lee CM, et al
    CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses.
    J Clin Invest. 2021;131.
    

    >> Share

    
    October 2021
16. PERI A, Greenstein E, Alon M, Pai JA, et al
    Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.
    J Clin Invest. 2021;131.
    

    >> Share

    
    
17. CHAKRABORTY B, Byemerwa J, Shepherd JH, Haines CN, et al
    Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.
    J Clin Invest. 2021 Oct 12. pii: 151347. doi: 10.1172/JCI151347.
    

    >> Share

    
    August 2021
18. VEATCH JR, Singhi N, Srivastava S, Szeto JL, et al
    A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells.
    J Clin Invest. 2021;131.
    

    >> Share

    
    May 2021
19. GIBLIN W, Bringman-Rodenbarger L, Guo AH, Kumar S, et al
    The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics.
    J Clin Invest. 2021 May 4. pii: 138926. doi: 10.1172/JCI138926.
    

    >> Share

    
    April 2021
20. KIM YJ, Sheu KM, Tsoi J, Abril-Rodriguez G, et al
    Melanoma dedifferentiation induced by interferon-gamma epigenetic remodeling in response to anti-PD-1 therapy.
    J Clin Invest. 2021 Apr 29. pii: 145859. doi: 10.1172/JCI145859.
    

    >> Share

    
    March 2021
21. WORREDE A, Douglass SM, Weeraratna AT
    The dark side of daylight: photoaging and the tumor microenvironment in melanoma progression.
    J Clin Invest. 2021;131.
    

    >> Share

    
    
22. HEEMSKERK N, Gruijs M, Temming AR, Heineke MH, et al
    Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.
    J Clin Invest. 2021;131.
    

    >> Share

    
    
23. HUANG F, Goncalves C, Bartish M, Remy-Sarrazin J, et al
    Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates anti-tumor immune responses.
    J Clin Invest. 2021 Mar 9. pii: 140752. doi: 10.1172/JCI140752.
    

    >> Share

    
    May 2020
24. LI J, Wang W, Zhang Y, Cieslik M, et al
    Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.
    J Clin Invest. 2020;130:2712-2726.
    

    >> Share

    
    
25. THEIVANTHIRAN B, Evans KS, DeVito NC, Plebanek M, et al
    A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
    J Clin Invest. 2020;130:2570-2586.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share